Seattle Genetics, Inc. (SGEN) Reaches $58.68 After 8.00% Down Move; 4 Analysts Covering Curis, Inc. (CRIS)

December 1, 2017 - By Michael Collier

The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) is a huge mover today! The stock decreased 3.69% or $2.25 during the last trading session, reaching $58.68. About 708,349 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since December 1, 2016 and is uptrending. It has outperformed by 58.98% the S&P500.The move comes after 7 months negative chart setup for the $8.45 billion company. It was reported on Dec, 1 by Barchart.com. We have $53.99 PT which if reached, will make NASDAQ:SGEN worth $675.68 million less.

Among 5 analysts covering Curis (NASDAQ:CRIS), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Curis had 7 analyst reports since August 10, 2015 according to SRatingsIntel. The stock has “Sell” rating by Zacks on Monday, September 21. The firm has “Outperform” rating given on Tuesday, August 11 by FBR Capital. The company was initiated on Monday, October 23 by Guggenheim. TH Capital maintained it with “Buy” rating and $5 target in Monday, November 9 report. The firm has “Buy” rating given on Monday, November 9 by Roth Capital. Zacks downgraded the shares of CRIS in report on Tuesday, September 1 to “Hold” rating. See Curis, Inc. (NASDAQ:CRIS) latest ratings:

23/10/2017 Broker: Guggenheim Rating: Buy New Target: $7.0 Initiate

Investors sentiment increased to 1.52 in Q2 2017. Its up 0.15, from 1.37 in 2017Q1. It improved, as 9 investors sold Curis, Inc. shares while 20 reduced holdings. 14 funds opened positions while 30 raised stakes. 72.75 million shares or 0.77% less from 73.32 million shares in 2017Q1 were reported. American Grp Inc Inc holds 71,918 shares. Jacobs Levy Equity Mgmt reported 0.01% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Strs Ohio invested in 48,500 shares or 0% of the stock. Tiaa Cref Invest Limited Liability Co stated it has 311,378 shares. Sg Americas Securities Lc holds 35,971 shares. Bb&T Limited Company reported 94,972 shares or 0% of all its holdings. Meridian Investment Counsel Incorporated stated it has 10,000 shares or 0.01% of all its holdings. First Eagle Investment Lc has invested 0.11% in Curis, Inc. (NASDAQ:CRIS). Sabby holds 0.01% or 48,000 shares. Alliancebernstein L P, New York-based fund reported 83,800 shares. D E Shaw And Inc holds 719,614 shares or 0% of its portfolio. Creative Planning reported 0% stake. Natl Bank Of New York Mellon Corp has 359,352 shares for 0% of their portfolio. Nationwide Fund Advsrs reported 65,147 shares. Ameritas Inc has 0% invested in Curis, Inc. (NASDAQ:CRIS).

The stock increased 10.65% or $0.08 during the last trading session, reaching $0.88. About 4.68M shares traded or 281.56% up from the average. Curis, Inc. (NASDAQ:CRIS) has risen 2.47% since December 1, 2016 and is uptrending. It has underperformed by 14.23% the S&P500.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $144.31 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

Analysts await Seattle Genetics, Inc. (NASDAQ:SGEN) to report earnings on February, 8. They expect $-0.44 EPS, down 12.82% or $0.05 from last year’s $-0.39 per share. After $-0.19 actual EPS reported by Seattle Genetics, Inc. for the previous quarter, Wall Street now forecasts 131.58% negative EPS growth.

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 7 have Buy rating, 0 Sell and 11 Hold. Therefore 39% are positive. Seattle Genetics had 56 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Monday, June 19 with “Buy”. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Hold” rating by Bank of America on Friday, October 27. The firm has “Neutral” rating given on Friday, October 30 by Piper Jaffray. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Buy” rating by RBC Capital Markets on Monday, November 13. The rating was maintained by Needham with “Buy” on Monday, October 23. SunTrust maintained Seattle Genetics, Inc. (NASDAQ:SGEN) on Tuesday, October 3 with “Hold” rating. Piper Jaffray maintained Seattle Genetics, Inc. (NASDAQ:SGEN) rating on Friday, October 27. Piper Jaffray has “Hold” rating and $55.0 target. The stock has “Outperform” rating by RBC Capital Markets on Tuesday, December 6. Goldman Sachs upgraded the stock to “Neutral” rating in Thursday, September 15 report. Cowen & Co maintained the stock with “Hold” rating in Tuesday, June 6 report.

Investors sentiment decreased to 1.3 in Q2 2017. Its down 0.20, from 1.5 in 2017Q1. It is negative, as 30 investors sold Seattle Genetics, Inc. shares while 75 reduced holdings. 48 funds opened positions while 89 raised stakes. 137.48 million shares or 0.82% less from 138.62 million shares in 2017Q1 were reported. Prelude Cap Management Ltd Liability Company stated it has 0.02% in Seattle Genetics, Inc. (NASDAQ:SGEN). National Bank Of Montreal Can has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). The Georgia-based First City Capital has invested 0.2% in Seattle Genetics, Inc. (NASDAQ:SGEN). Blair William & Co Il has invested 0.26% in Seattle Genetics, Inc. (NASDAQ:SGEN). Tourbillon Capital Ptnrs L P owns 640,000 shares. Capstone Inv Limited Liability Co holds 31,700 shares or 0.04% of its portfolio. Vantage Investment Advsr Limited Liability, a Pennsylvania-based fund reported 600 shares. Caxton Assoc Ltd Partnership invested in 5,200 shares. Fairfield Bush And accumulated 16,772 shares or 0.28% of the stock. Eagle Asset Mngmt holds 299,804 shares. Alpha Windward Ltd Com invested in 0.01% or 379 shares. 5,035 are owned by Capstone Asset Mgmt. Assetmark has 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 193 shares. 1,900 were accumulated by Livforsakringsbolaget Skandia Omsesidigt. British Columbia Invest Mgmt holds 48,557 shares.

Since May 31, 2017, it had 0 insider purchases, and 1 insider sale for $679,698 activity. HIMES VAUGHN B sold $625,922 worth of stock or 10,000 shares. SIEGALL CLAY B also sold $679,698 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, June 5.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>